Adiposity, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Pre-Eclampsia, Procalcitonin, Sepsis, SIRS
Conditions
Brief summary
Procalcitonin is a protein consisting of 116 amino-acids which can rapidly rise under inflammatory conditions and sepsis. More than 20 years ago it has been shown that dipeptidylpeptidase-4 (DPP-4) cleaves procalcitonin from the n-terminus, resulting in a truncated procalcitonin-variant which consists of 114 aminoacids. Within their workgroup the investigators found that the truncated procalcitonin-variant had deleterious effects on vascular integrity during sepsis in mice. However, it is unknown if this applies also in humans. By using an ELISA-assay the investigators want to examine the ratio between native and truncated human procalcitonin during diseases accompanied with hyperprocalcitoninemia and correlate the results with clinical data.
Detailed description
Procalcitonin is a protein consisting of 116 amino-acids which can rapidly rise under inflammatory conditions and sepsis. More than 20 years ago it has been shown that dipeptidylpeptidase-4 (DPP-4) cleaves procalcitonin from the n-terminus, resulting in a truncated procalcitonin-variant which consists of 114 aminoacids. Within their workgroup the investigators found that the truncated procalcitonin-variant had deleterious effects on vascular integrity during sepsis in mice: They observed that binding of truncated procalcitonin to the CRLR/RAMP1-receptor on vascular endothelium lead to phosphorylation and destruction of VE-cadherin, an essential part of adherens junctions. Consequently, paracellular leakage of proteins and fluid from blood vessels developed. It is unknown if these effects also apply to humans. By using an ELISA-assay the investigators want to examine the ratio between native and truncated human procalcitonin during diseases accompanied with hyperprocalcitoninemia and correlate the results with clinical data. Futhermore, they want to examine if the procalcitonin-variants have influence on cytokine levels and surface antigens on immune cells by performing multiplex immunoassays and FACS-analysis.
Interventions
DIAGNOSTIC_TESTProcalcitonin-variants ELISA-Assay
Observational study measuring procalcitonin-variants in different patient collectives by obtaining 3 blood collection tubes per patient.
Sponsors
University Hospital Muenster
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Age \>18 * Patients with diagnosis... * Sepsis or, * SIRS after cardiothoracic surgery or, * adipositas or, * granulomatosis with polyangiitis/microscopic polyangiitis or, * pre-eclampsia * healthy control subjects * written informed consent
Exclusion criteria
* participation in an interventional study trial within the last 3 months * relationship to study investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ratio between native and truncated procalcitonin during different conditions of hyperprocalcitoninemia | Blood withdrawal takes approximately 5 minutes per patient | Measurement performed by using ELISA-assay. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| DPP-4-activity | Blood withdrawal takes approximately 5 minutes per patient | Measurement performed by using a commercial DPP4-ELISA-kit. |
| Proinflammatory cytokines | Blood withdrawal takes approximately 5 minutes per patient | Measurement performed by using a commercial multiplex immunoassay kit. |
| Immun cell surface-antigens | Blood withdrawal takes approximately 5 minutes per patient | Measurement performed by using fluorescence-acivated cell sorting (FACS). |
Countries
Germany
Outcome results
None listed